Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in advanced renal cell carcinoma and malignant melanoma
ChiCTR2300068189Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and sunitinib in renal cell carcinoma (RCC) and melanoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumabsunitinib
03
Conditions
renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on ChiCTR2300068189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068189.